パーキンソン病の臨床前モデルにおいて,ポリメリックナノ粒子媒介のGBA1遺伝子療法は神経保護的である
Mohit Kwatra1,2,3, Gijung Kwak4,5, Haolin Li4,5,6
1Institute for Cell Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, 21205, USA.
Drug delivery and translational research
|August 21, 2025
まとめ
No abstract available in PubMed .
さらに関連する動画
関連する概念動画
Parkinson's Disease: Treatment
377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
Gene Therapy
25.8K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.8K
Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703


